In addition, the present cutoff score for high c-Met expression might be similar to what was used in a previous study that examined the use of c-Met inhibitor cabozantinib in ccRCC treatment, where patients with high c-Met expression (≥2+ staining in 50% of tumor cells) presented survival benefit from receiving cabozantinib therapy compared to the group taking sunitinib, but those without high c-Met expression did not [33]. This evidence concerns the gene MET and nonpapillary renal cell carcinoma.